Description:

The objective of the study is to determine if men with evidence of progressive prostate cancer while on chronic androgen ablation of = 1 year duration will exhibit a clinical response following administration of parenteral testosterone and oral etoposide.  Eligible patients will have castrate resistant prostate cancer with minimal disease (rising PSA and = 5 total sites of metastases in bone, lymph node and soft tissue) on continuous castrating androgen ablative therapy for = 1 yr; allowed = 2 prior chemo; allowed = 2 prior second line HT; off antiandrogens for = 6weeks

Link:

http://clinicaltrials.gov/ct2/show/NCT01084759

Site:

Johns Hopkins Hospital

Principal Investigator:

Samuel Denmeade, M.D.